No point on repeating ANA testing PPV 0.01 according to this abstract by Yeo et al. #EULAR2019 #Rheumatology @RheumNow https://t.co/kX0angBvqd

Full house in Jaki and beyond session. S Cohen presented fenebrutinib a BTK inhibitor at doses including 200 mg bid is in TNFI-IR or Mtx-IR active pts with RA in a Phase II RCT. 12 week data were similar to adalimumab. New pathway for RA Rx maybe #OP0025 https://t.co/avLSopLju6

Fantastic talk by Georgios Filippou highlighting how we can use US to help us differentiate DDx and clinical phenotypes. #eular2019 @RheumNow https://t.co/hxKqrziDSN

Romosozumab has dual effect: bone-forming AND preventing resorption. Hitting hard with this early in #osteoporosis reduces fracture risk later when on denosumab, compared to those receiving placebo prior. Similar results when patients switch to alendronate. @RheumNow #EULAR2019 https://t.co/ZSQAxSUnv9

With OA therapeutics, there’s disease, and then there’s illness. Any disease modifying effect that might be there can get drowned out by fibromyalgia... Data on lorecivivint in Marc Hochberg’s anabolic DMOAD overview SP0013 #EULAR2019 @RheumNow https://t.co/GALk9hs8KB

Filippou shows us US vs synovial exam of crystal: US more sensitive but less specific than synovial aspirate. Beware the double contour sign in CPPD mimicking gout but calcification moves discordant with the bone. #eular2019 @RheumNow https://t.co/W8pftdfa0I

OA is multifactorial. So why do we expect a silver bullet therapeutic solution? Rik Lories on manipulating signaling pathways for treating OA #EULAR2019 SP0013 @RheumNow https://t.co/0g2ZLT4XfN

@benjaminsutu @dr_rachelblack @tuna0sashimi @RheumNow You want puns? We got puns https://t.co/MxGSOE9BI7

Do NSAIDs work in Axial Spondyloarthritis? YES! The all work but none is better or safer than the others #EULAR 2019 abstr SP0003 https://t.co/z2Dp8Cf2PV

The very first WIN and HOT session is about to begin. Join us as we explore ‘New Avenues of OA & Osteoporosis Management’ in Hall 6 at 14.15.(CEST). See it on the move on @YouTubeTV #EULARLIVE: https://t.co/LojAOi4cAZ https://t.co/eoggidKWZ9

Acetaminophen had more diarrhea and transaminitis than placebo in RCTS. In nonrandomized studies there were 1.4 times more UGI bleeds but likely channeling bias. Ok for CV events in RCTs; mixed results in uncontrolled studies for CV and renal. @RheumNow #EULAR2019 0P0019-HPR https://t.co/Y8f87jnxbR